AlphAIAlphAI — Financial news for AI agents
stocktitan.netSEP 222 min read

PDS Biotechnology gets 19.9% Nant Capital stake

PDS Biotechnology (PDSB) disclosed that Nant Capital, led by Patrick Soon-Shiong, acquired a 19.9% stake in the company. Nant Capital purchased 13,005,334 shares and warrants for $0.2825 per share. The investment includes a milestone closing contingent on PDS0301's Phase 3 trial submission to the FDA, with Nant Capital obligated to invest $10M. Soon-Shiong and James Banaag joined PDS Biotechnology's board.

Original reporting
stocktitan.net
Published Sep 22, 2026, 2:18 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 22, 2026, 3:27 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$PDSB
Relevance
6/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

Med
01

Why it matters

The filing introduces a new large shareholder with board influence and a contingent $10M milestone purchase, which could affect governance and future financing.

02

Market read

Primary disclosure of a significant ownership stake and financing terms for a microcap biotech, modest trading relevance.

03

What to watch

Future FDA filing milestone could trigger larger capital moves if successful.

Relevance 6/10Novelty 6/10Timing: post-September 7 2026 filing

Background

PDS Biotechnology filed a Schedule 13D reporting a 19.9% stake acquisition by Nant Capital, board appointments, and a PIPE financing agreement.

Market effects

Sector

Potential signal for biotech financing activity and board composition trends.

Regional

Limited to US biotech microcap segment.

Global

Low global impact.

Counterpoint

What could challenge this read

Stake size may not move price significantly; market may already price in the investment.

Key entities

  • company
    PDS Biotechnology Corporation

    Biotech firm issuing common stock and warrants.

  • investor
    Nant Capital, LLC

    Investor acquiring 19.9% stake and board seats.

Read at source← All news

Related articles

OCT 16
$PDSBMed

PDS Biotechnology Targets Phase III Trial for PDS0301 in Metastatic Colorectal Cancer

PDS Biotechnology (NASDAQ: PDSB) is planning a Phase III trial for PDS0301 in metastatic colorectal cancer. Early studies showed promising results, with a 70% response rate at six months. The company has discussed the trial design with the FDA and aims to start the trial in early 2027. PDS0301 is being evaluated in combination with hepatic artery infusion pump therapy, which showed durable responses and manageable side effects.

finance.yahoo.com2 min
OCT 13
$PDSBMedAI 8/10

PDSB Jumps As JAMA Data And Nant Capital Deal Reshape The Story

PDS Biotechnology (PDSB) shares rose 13.08% on October 13, 2026, driven by positive clinical data and a financing deal. The company reported a 36% objective response rate in a Phase 2 trial published in JAMA Oncology, outperforming historical benchmarks. PDSB also secured $11.3M in funding from Nant Capital, though at a dilutive price. The stock's recent surge reflects optimism around its immunotherapy pipeline and strategic partnerships, despite its fragile financials.

stockstotrade.com6 min
SEP 22
$PDSBMedAI 8/10

PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic…

PDS Biotechnology Corp (PDSB) filed an SEC Form 8-K — Other Events. Exhibit 99.1 PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncology 39.3 months median overall survival in first-line (1L) R/M immune

SEC EDGAR 8-K2 min
SEP 8
$BJDXMedAI 8/10

5 Biotech Stocks To Watch: Bluejay, Pharvaris, Roivant, PDSB & Atara

Bluejay Diagnostics (BJDX) partnered with Lovell Government Services for federal healthcare market access, trading at $1.05, up 27.4%. Pharvaris (PHVS) reported 83% attack rate reduction in HAE study, trading at $37.82, up 7.02%. Roivant (ROIV) showed positive Phase 2 results for mosliciguat, trading at $41.35, up 18.35%. Atara Biotherapeutics (ATRA) updated BLA resubmission plans, trading at $10.71, up 9.73%. PDS Biotech (PDSB) raised $22.55M in PIPE financing, trading at $0.29, up 33.21%.

rttnews.com3 min